Depo-Provera Meningioma Brain Tumor Mass Tort Litigation represents an active product liability case involving thousands of women who allegedly developed benign brain tumors (meningiomas) after using Depo-Provera, a common injectable birth control medication. As of April 2026, over 3,490 cases are consolidated in MDL 3140 in the United States District Court for the Northern District of Florida under Judge M. Casey Rodgers, with plaintiffs’ attorneys reportedly holding approximately 10,000 additional unfiled claims. The litigation centers on scientific evidence linking the injectable contraceptive to a significantly elevated risk of meningioma requiring surgery, with the FDA adding meningioma warnings to the drug’s label in December 2025 after the manufacturer requested such warnings nearly a year earlier. The mass tort began in October 2024 when the first lawsuit was filed, rapidly accelerating after a March 2024 study published in the British Medical Journal found that women using Depo-Provera had a 5.5 times higher likelihood of developing a meningioma requiring surgical intervention compared to non-users.
For example, a woman in her 40s who used Depo-Provera for 10 years and subsequently developed a benign but symptomatic meningioma pressing on her brain would potentially be eligible to pursue compensation through this litigation. This case differs from typical drug litigation because the brain tumors involved are typically noncancerous; the harm derives from the need for invasive neurosurgery, potential neurological damage, and long-term health complications rather than from cancer itself. Currently, the litigation is in a critical phase focused on establishing the scientific and legal relationship between Depo-Provera use and meningioma development. No verdicts or settlements have been reached as of April 2026, though the first bellwether trial—a test case intended to inform settlement discussions—is scheduled for December 2026. Plaintiffs’ attorneys have indicated that eventual compensation settlements may range from $150,000 to $5 million depending on the severity of the diagnosis, intensity of treatment, and impact on quality of life, with historical meningioma litigation averaging settlements around $800,000 and trial verdicts exceeding $3 million.
Table of Contents
- How Many Cases Are in the Depo-Provera Meningioma Litigation?
- The Scientific Evidence Linking Depo-Provera to Meningioma
- FDA Regulatory Action and the Warning Label Update
- Current Status of the Litigation and the Bellwether Trial Process
- Estimated Compensation Ranges and How Verdicts Are Calculated
- Who Can File a Claim and What Documentation Is Required
- Future Outlook and Timeline for the Depo-Provera Meningioma Litigation
- Conclusion
- Frequently Asked Questions
How Many Cases Are in the Depo-Provera Meningioma Litigation?
The scope of this litigation extends far beyond the currently consolidated cases. MDL 3140 contains more than 3,490 filed cases as of April 2026, but this number represents only a fraction of potential claims. Plaintiffs’ attorneys across the country are reportedly holding approximately 10,000 additional unfiled cases in their offices, waiting to see how early bellwether trials proceed before filing them into the federal multidistrict litigation. This creates a substantial pipeline of potential cases that could dramatically expand the scope of the litigation once initial trials yield verdicts or settlement frameworks.
The rapid growth from the first lawsuit in October 2024 to over 3,490 consolidated cases within 18 months demonstrates the widespread reach of Depo-Provera use among American women. The drug has been on the market since 1992 and was prescribed to millions of women as a reversible, long-acting contraceptive option. The combination of a well-established scientific link (the BMJ study), FDA label changes, and aggressive plaintiff recruitment has created significant momentum in this litigation. However, the existence of 10,000 unfiled claims also means that the true magnitude of the litigation remains uncertain—some of these claims may lack sufficient documentation, others may settle informally, and some may never be filed.
The Scientific Evidence Linking Depo-Provera to Meningioma
The foundation of this entire mass tort rests on a single pivotal study published in March 2024 in the British Medical Journal. This study found that women using Depo-Provera had a 5.5 times higher relative risk of developing a meningioma requiring surgery compared to women who had never used the injectable contraceptive. The study analyzed data from over 300,000 women and specifically examined surgical meningioma cases—meaning symptomatic tumors serious enough to warrant neurosurgery rather than incidental findings on brain imaging. This level of relative risk is substantial and medically significant, though the absolute risk of developing a meningioma remains relatively low even among users. It is important to understand what this scientific finding does and does not establish. The 5.5-fold increase in risk means that if the baseline risk of a non-user is 1 in 100,000 women, the risk for a Depo-Provera user might be approximately 5.5 in 100,000 women. The absolute risk still remains modest—most women who use Depo-Provera will never develop a meningioma.
However, from a litigation perspective, the relative risk figure is what matters. Thousands of women who used Depo-Provera have been diagnosed with meningiomas, and they are now asserting that the medication increased their individual risk of developing these tumors. one limitation of the study is that it cannot prove causation in individual cases—it establishes a statistical association at the population level, which is the basis for product liability claims but not absolute proof in any particular person’s circumstances. The mechanism by which Depo-Provera might cause meningioma is not fully understood. Meningiomas are hormone-sensitive tumors, and research suggests they contain progesterone receptors. Depo-Provera is a progestin (synthetic progesterone), so theoretically, exposure to this hormone could stimulate growth of dormant meningioma cells or increase the transformation of normal cells into meningioma tissue. However, neither the BMJ study nor subsequent research has definitively established the biological mechanism, which remains an open question in the litigation.
FDA Regulatory Action and the Warning Label Update
On December 12, 2025, the FDA approved significant changes to the warning labels for both Depo-Provera CI and Depo-SubQ Provera 104, adding increased risk of meningioma to the labeled warnings. This regulatory action represents a formal acknowledgment by the FDA that the risk is real enough to warrant explicit communication to healthcare providers and patients. The timing of this label change is noteworthy: Pfizer, the manufacturer, reportedly submitted a formal request to the FDA for a meningioma warning in 2024, and according to Pfizer’s own statements, that request was allegedly blocked or delayed for several months before the December 2025 approval finally occurred. The FDA label change itself does not determine liability in the litigation—it does not establish that Depo-Provera caused any individual woman’s meningioma, nor does it confirm Pfizer’s claim that it was unjustly prevented from warning doctors earlier. However, the label change is significant evidence that plaintiffs’ attorneys will cite in litigation.
A jury might reasonably infer that if the FDA ultimately agreed the meningioma risk was serious enough to label, and if Pfizer was pushing for earlier warnings, then the risk was both real and perhaps inadequately communicated to doctors and patients before the official label update. The limitation here is that the FDA’s approval of a label change does not necessarily mean the FDA believes Pfizer acted wrongfully—it may simply mean the agency agreed that the risk warranted disclosure going forward. The dispute over timing—whether Pfizer’s alleged 2024 warning request was blocked—will likely become a focal point in litigation. If evidence emerges showing Pfizer wanted to warn doctors about meningioma risk earlier but was prevented from doing so, that could support claims that the company failed to warn healthcare providers adequately. Conversely, if Pfizer’s account is inaccurate, that narrative advantage disappears. This factual dispute will be heavily litigated in both bellwether trials and settlement negotiations.
Current Status of the Litigation and the Bellwether Trial Process
As of April 2026, no verdicts have been reached and no settlements have been finalized in the Depo-Provera meningioma litigation. The case is being managed by Judge M. Casey Rodgers in the Northern District of Florida, who oversees all consolidated cases in MDL 3140. The next critical milestone is the first bellwether trial scheduled for December 2026—approximately eight months away from the current date. A bellwether trial is essentially a test case where one or two representative cases go to trial first, the jury renders a verdict, and that verdict informs settlement discussions for the remaining thousands of cases. In bellwether trials, both sides typically select cases that represent the “middle ground” of potential claims—neither the most sympathetic plaintiffs nor the weakest cases, but rather representative examples. A plaintiff in a bellwether trial might be a woman who used Depo-Provera for 5-10 years and subsequently developed a meningioma that required surgery and resulted in some permanent neurological effects but not total disability.
The outcome of the December 2026 trial will substantially influence how the remaining 3,490 consolidated cases and the 10,000 unfiled cases are resolved. If the verdict is high, defendants will likely pursue broad settlement discussions. If the verdict is low, litigation will likely continue for years. The practical implication for women with potential claims is that timing matters. Those with documented Depo-Provera use and a meningioma diagnosis should consult with attorneys soon, but the litigation timeline suggests that most resolution will not occur until late 2026 or later. The advantage of waiting to see bellwether results is that settlement values will become clearer; the disadvantage is that statutes of limitations may expire, and memories fade. Attorneys representing plaintiffs will help navigate this timeline, but patience and realistic expectations are necessary during this waiting period.
Estimated Compensation Ranges and How Verdicts Are Calculated
Based on historical meningioma litigation and similar product liability cases, compensation in Depo-Provera litigation is estimated to range from $150,000 to $5 million per case, depending on several factors. Average settlements in comparable meningioma litigation have exceeded $800,000, while average trial verdicts in meningioma cases have surpassed $3 million. These figures provide a rough framework, but individual case values will vary dramatically based on specific circumstances. A key limitation of these estimates is that no actual Depo-Provera meningioma settlement or verdict yet exists, so these ranges are extrapolated from other product liability litigation and cannot be guaranteed to apply in this specific case. Several factors determine individual claim value in this litigation. First, age and life expectancy matter significantly—a 30-year-old woman diagnosed with a meningioma has a longer remaining lifespan and greater lifetime medical costs and lost wages than a 65-year-old. Second, the severity and permanence of neurological effects directly impact value—a woman who required surgery and continues experiencing chronic headaches, balance problems, or cognitive changes will receive higher compensation than someone whose meningioma was treated without lasting complications. Third, the duration and extent of Depo-Provera use may influence valuation, with longer-term users potentially receiving larger awards on the theory that they faced greater cumulative exposure.
Fourth, medical expenses—both past surgery and ongoing treatment—add to the award amount. Fifth, lost wages and reduced earning capacity from inability to work contribute substantially to larger verdicts. A hypothetical example illustrates how compensation might be calculated. Consider a 35-year-old woman who used Depo-Provera for 12 years, developed a meningioma requiring neurosurgery, and experienced permanent partial numbness and weakness on her left side. Her medical bills total $200,000 and she cannot return to her career as a software engineer, reducing her lifetime earnings by an estimated $500,000. Attorneys might seek $1.2 million in past and future economic damages, plus additional amounts for pain, suffering, and loss of quality of life—potentially reaching $1.8 to $2.5 million in total demand. This case would fall in the moderate-to-higher range of potential claims. Conversely, a woman with a meningioma that was removed successfully without permanent effects might settle for $300,000 to $600,000. The wide range reflects the reality that not all meningioma cases are equally severe.
Who Can File a Claim and What Documentation Is Required
Eligibility for the Depo-Provera meningioma litigation is relatively straightforward: a woman must have used Depo-Provera (either Depo-Provera CI or Depo-SubQ Provera 104) at some point and subsequently been diagnosed with a meningioma. Medical documentation of both the contraceptive use and the meningioma diagnosis is essential. For Depo-Provera use, relevant documentation includes pharmacy records, prescriptions, medical records from the prescribing doctor, or billing statements from the healthcare provider. For the meningioma diagnosis, a copy of the pathology report from the surgical specimen, brain imaging reports (MRI or CT scans), and neurosurgery records documenting the diagnosis and treatment are necessary.
One important distinction in this litigation is that the meningioma does not need to be malignant or life-threatening to support a claim—in fact, most meningiomas are benign (noncancerous). What matters is that the woman developed a meningioma serious enough to warrant surgical intervention and that she can establish she used Depo-Provera. A woman whose meningioma was discovered incidentally on an MRI taken for another reason and never treated might still have a viable claim, though the claim value would be lower because she avoided the risks and costs of surgery. The strongest claims typically involve women who underwent meningioma surgery, experienced complications or permanent effects, and can document clear medical necessity for the procedure.
Future Outlook and Timeline for the Depo-Provera Meningioma Litigation
The December 2026 bellwether trial will be the pivotal event shaping the future of this litigation. If plaintiffs prevail with a substantial verdict, the litigation will likely accelerate toward global settlement negotiations, potentially resolving hundreds or thousands of cases within 12-18 months. If defendants succeed in the bellwether trial or win by a narrow margin, litigation will likely continue for several more years, with additional trials and gradual case-by-case settlements. This uncertainty is inherent in all mass tort litigation and makes precise timeline predictions impossible.
Looking forward, the litigation will likely reach some form of resolution by 2027 or 2028, given the current momentum and the scheduled bellwether trial. However, women with potential claims should not assume their cases will settle quickly or at anticipated values. Product liability litigation involving pharmaceuticals is complex, involving expert testimony about epidemiology, pharmacology, medical causation, and regulatory compliance. The fact that over 10,000 cases remain unfiled suggests the litigation will continue expanding for at least another 1-2 years. Women who believe they have a claim should consult with an attorney experienced in mass tort litigation as soon as possible to ensure they do not miss applicable filing deadlines or statutes of limitations.
Conclusion
The Depo-Provera Meningioma Mass Tort Litigation represents an active and growing product liability case involving thousands of women who developed brain tumors after using this widely prescribed injectable contraceptive. With over 3,490 cases consolidated in federal court as of April 2026 and approximately 10,000 additional unfiled claims held by attorneys, the litigation has reached a critical juncture. The scientific evidence from the March 2024 BMJ study, combined with the FDA’s December 2025 label update, provides substantial support for plaintiffs’ claims that Depo-Provera use significantly increases the risk of meningioma requiring surgical intervention. The first bellwether trial in December 2026 will determine whether this litigation results in a broad settlement or continues as protracted litigation.
If you believe you have a potential claim because you used Depo-Provera and were subsequently diagnosed with a meningioma, contact an experienced mass tort attorney immediately. Do not delay—statutes of limitations apply, and early consultation will help you understand your specific circumstances, the likely value of your claim, and the timeline for potential compensation. While settlement values remain uncertain pending the bellwether trial, historical meningioma litigation suggests claims could range from $150,000 to $5 million depending on severity and documented impact, with an average expectation around $800,000 for settlements and potentially higher for verdicts. The litigation is far from resolution, but the legal framework is in place for eligible women to seek compensation for the harm caused by this medication.
Frequently Asked Questions
What is Depo-Provera, and why is it being sued?
Depo-Provera is an injectable form of contraception that has been on the market since 1992. It is being sued because a March 2024 scientific study found that women using Depo-Provera were 5.5 times more likely to develop a meningioma (benign brain tumor) requiring surgery compared to non-users. The FDA added this warning to the medication’s label in December 2025.
How many cases are in this litigation?
Over 3,490 cases are consolidated in MDL 3140 in federal court as of April 2026, with attorneys reportedly holding approximately 10,000 additional unfiled cases. The litigation continues to grow as more women become aware of the link between Depo-Provera and meningioma.
Do I have to have had cancer to file a claim?
No. Most meningiomas are benign (noncancerous). The litigation focuses on any meningioma serious enough to require surgical intervention, regardless of whether the tumor was cancerous. The harm stems from the need for invasive neurosurgery and potential permanent neurological effects.
What compensation can I expect if I have a claim?
Based on historical meningioma litigation, compensation typically ranges from $150,000 to $5 million depending on severity. Average settlements in similar cases exceed $800,000, while average trial verdicts exceed $3 million. Your specific case value will depend on your age, the severity of your condition, medical expenses, and lost wages.
When will this litigation be resolved?
No verdicts or settlements have been reached as of April 2026. The first bellwether trial is scheduled for December 2026 and will heavily influence how remaining cases are resolved. Most settlement activity is expected to occur in 2027 or 2028, but litigation may continue longer depending on trial outcomes.
What documentation do I need to file a claim?
You will need medical records proving both Depo-Provera use (pharmacy records, prescriptions, or medical records from your doctor) and your meningioma diagnosis (pathology reports, brain imaging reports, and surgery records). An attorney can help you gather and organize these documents.